Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

KRAS inhibitor

- PMLiVE

Roche’s lung cancer combination treatment improves long-term survival

Anti-TIGIT therapy tiragolumab plus Tecentriq offers better progression-free survival improvement after 2.5 years than Tecentriq alone

- PMLiVE

BMS’ Opdivo improves survival in early-stage lung cancer

Pre-surgical Opdivo improves survival in non-small cell lung cancer patients, reinforcing its efficacy in early-stage cancers

- PMLiVE

AZ’s Imfinzi combination shows promise in liver cancer

Combining Imfinzi with experimental monoclonal antibody tremelimumab improved overall survival in patients with the most common form of liver cancer

- PMLiVE

Amgen’s Biosimilar Trends Report shows benefit of competition from biosimilars

Competition created by biosimilars has delivered $9.8bn in savings over five years and could reduce patients’ out-of-pocket costs by $238m

Roche Basel Switzerland

New data for Tecentriq in early-stage lung cancer

Roche’s PD-L1 blocker reduced the risk of disease recurrence and death for patients with stage 2-3a non-small cell lung cancer following surgery

- PMLiVE

AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients

The drug tripled patient survival after three years in the longest-ever follow-up in extensive-stage small cell lung cancer

- PMLiVE

Green light for Amgen’s KRAS inhibitor in the UK

Lumakras – known as Lumykras in the UK – will be available to 600 lung cancer patients in England through an early access scheme.

- PMLiVE

Tezepelumab effective in severe asthma with comorbid nasal polyps

Amgen’s novel drug offers hope to the one-in-five people with severe asthma who also have nasal polyps

- PMLiVE

New data advances AstraZeneca’s “revolution in oncology”

In a busy few weeks for AstraZeneca, the company will present data on 14 approved and potential drugs in lung and breast cancer

- PMLiVE

Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies

Amgen will gain antibody technologies designed to discover and develop new molecules with broad applications across therapeutic areas

- PMLiVE

FDA grants priority review for AZ, Amgen’s tezepelumab for asthma

Drug 'has the potential to transform treatment for a broad population of severe asthma patients'

- PMLiVE

AZ’s Tagrisso approved for EGFR-positive NSCLC in the EU

European Commission approved Tagrisso in this setting based on positive results from the ADAURA phase 3 study

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links